Cargando…

Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration

With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mrejen, Sarah, Jung, Jesse J., Chen, Christine, Patel, Samir N., Gallego-Pinazo, Roberto, Yannuzzi, Nicolas, Xu, Luna, Marsiglia, Marcela, Boddu, Sucharita, Freund, K. Bailey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519796/
https://www.ncbi.nlm.nih.gov/pubmed/26239682
http://dx.doi.org/10.3390/jcm4071380
_version_ 1782383555887759360
author Mrejen, Sarah
Jung, Jesse J.
Chen, Christine
Patel, Samir N.
Gallego-Pinazo, Roberto
Yannuzzi, Nicolas
Xu, Luna
Marsiglia, Marcela
Boddu, Sucharita
Freund, K. Bailey
author_facet Mrejen, Sarah
Jung, Jesse J.
Chen, Christine
Patel, Samir N.
Gallego-Pinazo, Roberto
Yannuzzi, Nicolas
Xu, Luna
Marsiglia, Marcela
Boddu, Sucharita
Freund, K. Bailey
author_sort Mrejen, Sarah
collection PubMed
description With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-VEGF injections/year (range 4–13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes.
format Online
Article
Text
id pubmed-4519796
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-45197962015-07-30 Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration Mrejen, Sarah Jung, Jesse J. Chen, Christine Patel, Samir N. Gallego-Pinazo, Roberto Yannuzzi, Nicolas Xu, Luna Marsiglia, Marcela Boddu, Sucharita Freund, K. Bailey J Clin Med Article With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-VEGF injections/year (range 4–13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes. MDPI 2015-07-08 /pmc/articles/PMC4519796/ /pubmed/26239682 http://dx.doi.org/10.3390/jcm4071380 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mrejen, Sarah
Jung, Jesse J.
Chen, Christine
Patel, Samir N.
Gallego-Pinazo, Roberto
Yannuzzi, Nicolas
Xu, Luna
Marsiglia, Marcela
Boddu, Sucharita
Freund, K. Bailey
Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title_full Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title_fullStr Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title_full_unstemmed Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title_short Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
title_sort long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519796/
https://www.ncbi.nlm.nih.gov/pubmed/26239682
http://dx.doi.org/10.3390/jcm4071380
work_keys_str_mv AT mrejensarah longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT jungjessej longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT chenchristine longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT patelsamirn longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT gallegopinazoroberto longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT yannuzzinicolas longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT xuluna longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT marsigliamarcela longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT boddusucharita longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration
AT freundkbailey longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration